Trial · NCT03346902
Study of EB-001 in Facial Scar Reduction
NCT03346902, Phase 2, Completed, Bonti, Inc.; results first posted 2018-12-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of EB-001 in Facial Scar Reduction. Trials, record NCT03346902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03346902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of EB-001 in Facial Scar Reduction
- NCT number
- NCT03346902
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Bonti, Inc.
- Conditions
- Mohs Surgery
- Interventions
- EB-001, 0.9% Sodium Chloride Injection
- First posted
- 2017-11-20
- Last updated
- 2019-01-08
- Results first posted
- 2018-12-14
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) | Day 30 | Assessment of change in Visual Analog Scale score (values from 0 (worst) to 10 (best)) from day of surgery to Day 30. Percentage of subjects reporting an improvement in Visual Analog Scale score. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) | Day 30 | mITT | Percentage reporting improvement | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) | Placebo | 0 | Percentage reporting improvement | ||
| Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) | EB001 | 50 | Percentage reporting improvement |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 4 | |
| Overall Study | STARTED | EB001 | 8 | |
| Overall Study | COMPLETED | Placebo | 4 | |
| Overall Study | COMPLETED | EB001 | 8 | |
| Overall Study | NOT COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | EB001 | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Asymmetry in facial features as a result of the temporal nerve being affected during the Mohs Surger | Nervous system disorders | Placebo | 0 | 4 | 0 |
| other | Asymmetry in facial features as a result of the temporal nerve being affected during the Mohs Surger | Nervous system disorders | EB001 | 1 | 8 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 4 |
| Total, all-cause mortality | EB001 | 0 | 8 |
| Total, other adverse events | Placebo | 0 | 4 |
| Total, other adverse events | EB001 | 1 | 8 |
| Total, serious adverse events | Placebo | 0 | 4 |
| Total, serious adverse events | EB001 | 0 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| EB001 vs Placebo: deaths from any cause | Trial comparisons |
| EB001 vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03346902
GET https://conductscience.org/api/trials/v1/NCT03346902/registered